Clinical experience of marketed Levetiracetam in an epilepsy clinic - a one year follow up study

被引:38
作者
Betts, T [1 ]
Yarrow, H [1 ]
Greenhill, L [1 ]
Barrett, M [1 ]
机构
[1] Univ Birmingham, Queen Elizabeth Psychiat Hosp, Seizure Clin, Birmingham B15 2QZ, W Midlands, England
来源
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY | 2003年 / 12卷 / 03期
关键词
Levetiracetam; audit; seizure freedom; retention rate; side effects; REFRACTORY EPILEPSY; PROFILE;
D O I
10.1016/S1059-1311(02)00258-3
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Levetiracetam is a new anti-convulsant with impressive pivotal trial credentials. We examined its effectiveness in refractory clinic patients with epilepsy with a year's follow up. Six months after initiation 32% of the patients were seizure free, and 26% at one year. By the end of the 12 months follow up 77% of patients were still taking the drug, having gained benefit from it: 23% had dropped out due to intolerable side effects, seizure increase or lack of efficacy. There is evidence that the drug is broad spectrum and as effective in primary generalised epilepsy as in partial onset epilepsy. Our audit of its use and effectiveness has led us to position it as our first choice add-on drug if the initial monotherapy drug fails. (C) 2002 BEA Trading Ltd. Published by Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:136 / 140
页数:5
相关论文
共 9 条
[1]  
BETTS T, 2002, IN PRESS SEIZURE, V11
[2]  
CERINGHO J, 2000, NEUROLOGY, V55, P236
[3]  
GREENHILL L, 2002, IN PRESS SEIZURE, V11
[4]   Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy [J].
Klitgaard, H ;
Matagne, A ;
Gobert, J ;
Wülfert, E .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 353 (2-3) :191-206
[5]   Long-term continuation of levetiracetam in patients with refractory epilepsy [J].
Krakow, K ;
Walker, M ;
Otoul, C ;
Sander, JWAS .
NEUROLOGY, 2001, 56 (12) :1772-1774
[6]   Early identification of refractory epilepsy. [J].
Kwan, P ;
Brodie, MJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (05) :314-319
[7]   Refractory epilepsy: a progressive, intractable but preventable condition? [J].
Kwan, P ;
Brodie, MJ .
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2002, 11 (02) :77-84
[8]   THE NOVEL ANTIEPILEPTIC DRUG LEVETIRACETAM (UCB L059) APPEARS TO ACT VIA A SPECIFIC BINDING-SITE IN CNS MEMBRANES [J].
NOYER, M ;
GILLARD, M ;
MATAGNE, A ;
HENICHART, JP ;
WULFERT, E .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 286 (02) :137-146
[9]   Pharmacokinetic profile of levetiracetam: toward ideal characteristics [J].
Patsalos, PN .
PHARMACOLOGY & THERAPEUTICS, 2000, 85 (02) :77-85